HDAC4-IN-1 

HDAC4-IN-1 (compound 1a) is a class IIa HDACI inhibitor (IC₅₀=0.077 μM). HDAC4-IN-1 can enhance Caspase-induced Apoptosis. HDAC4-IN-1 has anticancer activity. HDAC4-IN-1 can be used in the research of drug combination against cancer^[1].

HDAC4-IN-1 can significantly inhibits class IIa HDAC (IC₅₀=0.077 μM)^[1].
HDAC4-IN-1 (100 μM; 72 h) has very low cytotoxicity in THP-1 cells (IC₅₀=9.2 μM), but has a strong synergistic effect in combination with BTZ and enhances the cytotoxic effect of BTZ on cells ^[1].
HDAC4-IN-1 (5μM; 48 h) combines with BTZ (7.9 nM) can induce Caspase-mediated apoptosis in THP-1 cells^[1].
HDAC4-IN-1 (5μM; 24 h) combines with BTZ (7.9 nM) can enhance the expression of p21 protein in THP-1 cells ^[1].
HDAC4-IN-1 (5μM; 72 h) inhibits cell proliferation in cancer cell line Cal27_HDAC4 ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

356.34

C₁₆H₁₉F₃N₄O₂

1418293-39-6

O=C(NCCN(CC)CC)C1=CC=C(C2=NOC(C(F)(F)F)=N2)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Asfaha Y, et al. 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib. Eur J Med Chem. 2023 Nov 10;263:115907.  [Content Brief]